Inhibitors of tyk2
US-2024425484-A1 · Dec 26, 2024 · US
P38 MAP kinase inhibitors
US8975285B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8975285-B2 |
| Application number | US-201314139982-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 24, 2013 |
| Priority date | Oct 2, 2008 |
| Publication date | Mar 10, 2015 |
| Grant date | Mar 10, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
There are provided inter alia compounds of formula (I) wherein R 1 , Ar, L, X, R 3 and Q are as defined in the specification for use in therapy, especially in the treatment of inflammatory diseases.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for the therapeutic treatment of COPD comprising administering to a subject in need thereof an effective amount of a compound of the formula wherein R 1 is C 1-6 alkyl optionally substituted by a hydroxyl group; R 2 is H or C 1-6 alkyl optionally substituted by a hydroxyl group; R 3 is H, C 1-6 alkyl or C 0-3 alky…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8975285B2 cover?
- There are provided inter alia compounds of formula (I) wherein R 1 , Ar, L, X, R 3 and Q are as defined in the specification for use in therapy, especially in the treatment of inflammatory diseases.
- Who is the assignee on this patent?
- Respivert Ltd
- What technology area does this patent fall under?
- Primary CPC classification C07D401/14. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 10 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).